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Available online 1 April 2012Co-culture of periodontal ligament (PDL) fibroblasts and SCC-25 oral squamous carcinoma cells
(OSCC), results in conversion of PDLs into carcinoma-associated fibroblasts (CAFs). Paracrin
circuits between CAFs and OSCC cells were hypothesized to regulate the gene expression of matrix
remodeling enzymes in their co-culture, which was performed for 7 days, followed by analysis of
the mRNA/protein expression and activity of metalloproteinases (MMPs), their tissue inhibitors
(TIMPs) and other relevant genes. Interleukin1-β, transforming growth factor-β1, fibronectin and
αvβ6 integrin have shown to be involved in the regulation of the MMP and TIMP gene expression
in co-culture of CAFs and tumor cells. In addition, these cells also cooperated in activation of MMP
pro-enzymes. It is particularly interesting that the fibroblast-produced inactive MMP-2 has been
activated by the tumor-cell-produced membrane-type 1 matrix metalloproteinase (MT1-MMP).
The crosstalk between cancer- and the surrounding fibroblast stromal-cells is essential for the fine
tuning of cancer cells invasivity.
© 2012 Elsevier Inc.Open access under CC BY-NC-ND license.Keywords:
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One of the most predictive factors of poor clinical outcome of head
and neck squamous cell carcinoma (HNSCC) is the presence of
regional lymph nodemetastasis, and nodal status of the neck plays a
decisive role in the choice of treatment [1]. Hensen et al. recently
reported an independent gene expression analysis of metastasized75.
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C BY-NC-ND license.versus non-metastasized HNSCC. This analysis revealed differential-
ly expressed gene sets involved in the progression of HNSCC,
including extracellular matrix (ECM) remodeling- (i.e. matrix
metalloproteinases, (MMPs)), hypoxia- and angiogenesis-related
genes [2]. Interestingly, a similar gene profiling assay performed
over 10 years ago by Villaret et al. also showed overexpressed
matrix metalloproteinases in head and neck squamous cell carcino-(I. Kovalszky), mario.bitsche@i-med.ac.at (M. Bitsche),
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(MMP) activity and controlling the breakdown of ECM components,
also tissue inhibitors of metalloproteinases (TIMPs) play an
important role in the process of tumor invasion and metastasis [4].
TIMPs not only inhibit the catalytic activity of MMPs, but also are
able to act as growth factors and are involved in the activation or
inactivation of MMPs [5]. The signaling pathways and circles that
regulate MMPs and TIMPs are not fully understood.
Carcinoma-associated fibroblasts (CAFs) are able to promote
the growth of carcinoma cells [6]. CAFs induce an epithelial-to-
mesenchymal transition (EMT) in epithelial tumor cells, which is a
major biological process in invasion of squamous cell carcinoma
[7], progression and metastasis. During this process invasive
tumor cells tend to lose their epithelial antigens [8], their
epithelial cell polarity and morphology, and acquire mesenchymal
and stemness-related features [9,10]. In our recent reports we
have described a co-culture model of periodontal ligament (PDL)
fibroblasts and SCC-25 oral squamous carcinoma cells (OSCC),
which resulted in conversion of normal fibroblasts into CAFs. In
the same model EMT occurred in SCC-25 cells [11]. Moreover, we
have described that SCC-25 cells produce active, processed IL-1β,
and PDL fibroblasts possess receptor for it, whose expression is
increased in the presence of SCC-25 tumor cells. Upon interaction
with SCC-25 cells active IL-1β signaling occurs in co-cultured
fibroblasts leading to induction of several genes involved in tumor
progression, including interleukin-6 (IL-6) and prostaglandin-
endoperoxide synthase 2 (COX-2) [12]. As we reported before,
dynamic interaction between CAFs and tumor cells of HNSCC
dictates gene expression changes in the interacting cells, which
covers major events of tumor progression. Here, we hypothesize
that the paracrine interplay between SCC-25 carcinoma cells and
CAFs provides a mechanistic background for the gene regulation of
MMPs and TIMPs, which contributes to poor clinical outcome of
HNSCC. Traces of several regulatory pathways in the paracrine
interplay between SCC-25 carcinoma cells and CAFs were
acknowledged to determine the gene expression and the activa-
tion of matrix remodeling enzymes and their inhibitors.Materials and methods
Cell lines
PDL fibroblasts [11–13] were isolated from periodontal ligament
(PDL) and received from Prof. Dr. Miosge (Department of Prostho-
dontics, Georg-August-University, Göttingen, Germany) [13], they
were routinely cultured in DMEM-low glucose (PAA, Pasching,
Austria) supplemented with 10% foetal bovine serum (FBS) (PAA),
2 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomy-
cin. SCC-25 cells were purchased from the German Collection of
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany,
ref. ACC 617), and were routinely cultured in DMEM/F12 (PAA)
supplemented with 10% FBS (PAA), 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 units/ml penicillin, and 100 μg/ml streptomycin [11,12].
Co-culture
Co-culture between SCC-25 cells and PDL fibroblasts was de-
scribed in details before [11,12]. PDL fibroblasts were plated into
cell culture inserts and SCC-25 cells into the bottom of 6-wellplates [11,12], they were cultured in 1:1 mixedmedium of DMEM-
low glucose and DMEM/F12, supplemented with 10% FBS, and also
the single cultured control cells were cultured in the same
medium in order to have the same glucose concentration and
glycemic conditions in control and co-cultured conditions. The
medium in the co-cultures and in the controls was changed after
3 days. After letting them grow in co-culture for 7 days, the cells in
the inserts and in the wells were used for RNA isolation [11] or for
protein fractionation [12]. For gelatinase zymogram assay, the
media in the inserts and in the six-well-plates were replaced with
low-serum (0.3% FBS)-containing medium (a 1:1 mixed medium
of DMEM-low glucose and DMEM/F12 containing 0.3% FBS) for the
last 24 h. The conditioned medium was collected from the control
and co-cultured cells for gelatinase zymogram assay and for
combined immunoprecipitation–western blot [12], the potential
disturbing effect of serum-metalloproteinases was minimized in
this way. In a further run of experiments, co-cultured cells were
treated with 10−6 mol/L dexamethasone (Sigma, Vienna, Austria)
as previously reported [12,14].
Treatment of the cells with IL-1β
2×105/ml PDLs or SCC-25 cells were plated in 10% FBS-
supplemented-DMEM-low-glucose or in 10% FBS-supplemented-
DMEM/F12 (PAA) in 10 cm culture plates (Unilab, Innsbruck,
Austria). After 48 h, medium was replaced by 0.3% FBS-containing-
medium. Cells were treated with IL-1β at 0.015–1.5 ng/ml concen-
tration range for 4, 8 and 24 h as described before [12,15].
RNA extraction, reverse transcription and real-time RT-PCR
Total RNA was isolated and reverse transcribed from control
and co-cultured cells as described before, real-time RT-PCR was
done as referenced [11,16]. Several human PCR primers were
published previously: β-actin [17], MMP-1 [18], MMP-3 [19],
MMP-7 [20], MMP-9 [21], MMP-13 [22], TIMP-1 [23], TIMP-2
[24], TIMP-3 [25], TGF-β1 [26], Integrin αv [27]; fibronectin (FN)
and latent-transforming growth factor beta-binding protein-1
(LTBP-1) primers were taken from the NCI, Primer Viewer
Database, ref. nos. 11092, and 10108 respectively. Other primers
are listed in Supplementary Document 1. β-Actin functioned well
as a housekeeping gene [11], and did not show significant
changes in co-cultured conditions compared to controls. The
relative gene expression was calculated as previously reported
[16].
Protein expression and activity measurements
For the analysis of integrin αv, non-nuclear protein fractions were
subjected to western blot analysis [11] as described previously
[12,28]. Identical equal protein containing 20 μl samples were
loaded for western blot, which was performed either with the
JLA20 β-actin antibody (in 1:100 dilution), purchased from
Developmental Studies Hybridoma Bank (Iowa city, Iowa, USA)
as a loading control [29], or with rabbit polyclonal integrin αv
antibody (#4705, Cell Signaling Technology, Danvers, MA, USA, in
1:1000 dilution).
Conditioned media were collected from both the fibroblast and
the SCC-25 side of the co-culture and also from the control cells.
Fig. 1 – Summary of the suggested mechanism for the
regulation of MMPs and TIMPs in the paracrine interplay
between SCC-25 cells and fibroblasts. MMP-9 showed a tumor
specific expression, regulated presumably by the fibronectin
ITGA5B6 pathway. The ITGA5 was inducible in both SCC-25 and
PDL fibroblasts in co-culture, but ITGB6 expression was tumor
(SCC-25) specific. Based on a previous report [44], MMP-9
might be activated in interaction with CD-44, and according to
our gelatinase assay results, it remains bound with the tumor
cells (A). The results of this study suggest that MMP-2 is
secreted in its pro- (inactive-) form by CAFs surrounding the
tumor cells, and at a lower extent also by the tumor cells
themselves. Activation of MMP-2 either requires MT1-MMP
localized on the SCC-25 cancer cells [34], or integrins, where the
involvement of αv integrins (ITGA5) is expected (A).MMPs-1, -3
and TIMPs-1, -3 are produced in the PDL fibroblasts, and their
expression might be regulated by inflammatory cytokines,
including IL1-β produced by SCC-25 cells. The gene expression
of MMP-1, MMP-2, TIMP-1 and TIMP-3 was reduced by
dexamethasone (DEX) (B).
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and from both sides of the co-culture 20 μl medium was used
from all samples for gelatinase zymogram, and 200 μl samples
were used for immunoprecipitation [12] with 2 μl of rabbit poly-
or monoclonal antibodies (anti-MMP-2 #4022; anti-TIMP-1
#8946; anti-TIMP-3 #5673, Cell Signaling Technology). The
immunprecipitated samples were taken in 50 μl Laemmli-
sample-buffer [30] and 20 μl/well was loaded to 9 or 12%
acrylamide gels, followed by western blot [11] with the above-
mentioned antibodies. Comparable intracellular protein extracts
were reacted with the JLA20 β-actin antibody as loading
controls. Cells after co-culture and controls were scraped into
500 μl lysis buffer [31] (50 mM TRIS HCl (pH 7.5), 500 mM NaCl,
5 mM CaCl2)/well or /insert. Protein concentration was deter-
mined in the cell lysates, and 10 μg proteins were loaded to the
gelatin-containing gels from the lysates. The gelatinase assay
was performed as described previously [31]. Supernatants
represented conditioned medium of the cells, which was
pipetted off directly after completion of culture, lysates repre-
sented cells lysed after removal of conditioned medium, which
contained molecules bound on the cell surface, membrane-,
cytoplasmatic- and cell nuclear-fractions inclusive. Both super-
natants and lysates were subjected to polyacrylamide gel
electrophoresis using gelatin-containing 10% polyacrylamide
gels [31]. Gelatinase activity is recognized as white bands in colloidal
Coomassie Brilliant Blue G-250 (Roth, Karlsruhe Germany)-stained
gels. Density of the detected bands was measured by the Image J
software [11,16].
Immunocytochemistry and confocal microscopy
IBidi Dishes (Martinsried, Germany) with control and co-cultured
PDLs were used for fibronectin (primary antibody 1:40 diluted
(5 μg/ml); Santa Cruz Biotech., Santa Cruz, CA, USA, Cat. No.
sc59826, clone IST-9) immunocytochemistry after fixation with
methanol for 20 min at −20 °C, as described previously [12].
Immmunostained Ibidi dishes were evaluated by confocal micros-
copy [12].
ELISA
Conditioned media were collected from both the fibroblast and
the SCC-25 side of the co-culture and also from the control cells.
From the supernatant (conditioned media) of the control cells and
from both sides of the co-culture 100 μl mediumwas used from all
samples for quantitative TGF-β1 detection using the RayBio
human TGF-β1 ELISA Kit (RayBiotech, Norcross, GA, USA).
Statistical analysis
Each experiment was performed in three independent sets contain-
ing at least three biological repeats/set. The relative gene-expression
results were tested for normal distribution by D'Agostino and
Pearson omnibus normality test using the Graphpad Prism 4.03
(Graphpad Software Inc). Significance of changes in co-culture vs.
controls was tested by non-parametric tests (Mann–Whitney) and
Students' t-tests depending on the distribution of the data. The
independent experimental sets were then compared for reproduc-
ibility. Only reproducible changes with a p<0.05 level [11,12] were
considered as significant.Results
Model of the regulation of the paracrine interplay between
SCC-25 cells and CAFs
A continuous interaction between tumor cells and fibroblasts was
hypothesized in the regulation of MMP and TIMP expression and
activity. The expression of MMPs and TIMPs was expected in the
PDL fibroblasts, whose regulation was hypothesized to occur via
inflammatory cytokines, including IL1-β [32], produced by SCC-25
Fig. 2 – mRNA expression of MMP-1 (A), MMP-2 (B), MMP-3 (C), TIMP-1 (D), TIMP-3 (E) and MMP-9 (F) in PDL fibroblasts and SCC-25
cells in control and co-cultured conditions. *: p<0.05; **: p<0.01, ***: p<0.001.
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integrin αvβ6 (ITGA5B6) pathway was hypothesized. Another
possible pathway, especially in regulation of TIMP expression, is
the TGF-β1-pathway [31,32]; the expression of TGF-β1 was
expected in the fibroblasts and in the tumor cells (Fig. 1).Fibroblast contribution to the MMP and TIMP expression
in co-culture of SCC-25 cells and CAFs
Gene expression of MMPs-1, -2, -3, -7, -9 and -13 and TIMPs 1–3
was investigated in fibroblasts (PDLs) in control and co-cultured
Table 1 – Fibroblast contribution to the MMP and TIMP
expression in co-culture of SCC-25 cells and CAFs.
Gene: n Change in ﬁbroblast
co-culture related
to ﬁbroblast control
Test p
MMP-1 20 4±1-times up Mann–Whitney p=0.012
MMP-2 20 2.3±0.4-times up Mann–Whitney p=0.0047
MMP-3 20 3.15±0.6-times up Unpaired t test with
Welch's correction
p=0.02
MMP-7 20 Very low expression
MMP-9 20 Not detected
MT1-
MMP
20 Not detected
TIMP-1 20 3.15±0.6-times up Mann–Whitney p=0.014
TIMP-2 20 No change Mann–Whitney p=0.4
TIMP-3 20 5±0.8-times up Unpaired t test with
Welch's correction
p=0.008
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expressed in PDLs, and their gene expression was significantly
upregulated in co-cultured PDLs (Figs. 2A–E; Table 1). The
upregulation of MMP-2, TIMP-1 and TIMP-3 gene expression in
co-cultured PDLs has also been confirmed at protein level
(Figs. 3A–D). MMPs-7, -9 (Table 1) and -13 were not detected in
PDLs. TIMP-2 was also constitutively expressed in PDLs, and in co-
culture it was not significantly regulated (Table 1).Fig. 3 –Western blot analysis of MMP-2 (A, B), TIMP-1 (A, C) and TIM
in control (1–2) and co-cultured (3–4) conditions. Densitometry of
MMP-2 (B), TIMP-1 (C), TIMP-3 (D), *: p<0.05.Tumor cell contribution to the MMP and TIMP expres-
sion in co-culture of SCC-25 cells and CAFs
MMP-1 at low levels and MMP-9 at higher levels were constitu-
tively expressed in SSC-25 cells. In co-culture, their gene
expression was significantly upregulated compared to controls
(Figs. 2A, F; Table 2). Membrane-type 1 matrix metalloproteinase
(MT1-MMP) was also constitutively expressed in SSC-25 cells, in
co-culture, no significant regulation was observed in its gene
expression (Table 2). Although the expression compared to PDLs
in SCC-25 cells was low, TIMP-1 and TIMP-3 showed significant
upregulation in co-cultured SCC-25 cells (Figs. 2D–E, Table 2).
Regulation of MMPs and TIMPs expression in co-cultured
ﬁbroblasts
Based on our previous study, we investigated, if IL-1β [12,15]
contributed to the upregulation of MMPs-1–3 in PDLs. 24 h
treatment of PDLs with IL-1β at 1.5 ng/ml induced a significant
upregulation of MMP-1 (8.8±1.8-times; p=0.003 using unpaired
t-test with Welch's correction) and of MMP-3 (2.1±0.3-times,
p=0.012 using unpaired t-test with Welch's correction), while
MMP-2 was not upregulated. Similar to the gene expression of
MMPs, that of TIMPs was also investigated in 4–24 h treatment of
PDLs with IL-1β at 0.015–1.5 ng/ml. IL-1β did not change signifi-
cantly the gene expression of TIMP-1 and TIMP-3 in fibroblasts
(p=0.8 and 0.7 respectively, by one way analysis of variance). In a
further run of experiments, co-cultures were treated withP-3 (A, D) related to loading control (β-actin) in PDL fibroblasts
the detected bands normalized to the β-actin band densities.
1522 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 8 ( 2 0 1 2 ) 1 5 1 7 – 1 5 2 710−6 mol/L dexamethasone (DEX) as previously reported
[12,14]. The gene expression of both TIMP-1 and TIMP-3 showed
significant (p<0.01 using unpaired t-test with Welch's correc-
tion) decrease in DEX-treated co-culture compared to normal
one (0.4±0.1 (TIMP-1) and 0.3±0.1 TIMP-3 of the normal co-
culture after DEX treatment).
Another possible regulatory way of TIMPs expression is the
TGF-β1-pathway [31,32]. At mRNA level in PDLs and SCC-25 cells
TGF-β1 was expressed at comparable levels (Fig. 4A), and it was
significantly (p<0.002, using Mann Whitney test) upregulated in
co-culture in both of them (2.4±0.6-times in fibroblasts and 1.6±
0.1-times in SCC-25 cells) (Fig. 4A). At protein level the TGF-β1
expression in PDLs and SCC-25 cells was also comparable (8.5–
37.8 pg/ml). In co-culture, there was no significant regulation
either in supernatants of fibroblasts or SCC-25 cells compared
with controls (p>0.05 with non-parametric tests), and a
sustained expression of TGF-β1 was detectable in co-culture
using ELISA. The receptor TGFBR2 was constitutively expressed
in PDLs, in co-culture its gene expression was significantly
(p<0.05, using Student's t-test), 1.7±0.3-times increased in
them (Fig. 4B). For the activation of TGF-β1: latent TGFβ-binding
protein-1 (LTBP-1) is required [33], which was constitutively
expressed in high levels in PDLs (Fig. 4C), in co-culture, its gene
expression has not changed significantly (p=0.26, using Mann–
Whitney test) in them. Nevertheless, in SCC-25 cells there is a
significant (p<10−4, using Mann–Whitney test), 3.3±0.5-times
increase (Fig. 4C) in co-culture. TIEG (TGF-β1-inducible early
response gene) is used as a marker for the efficacy and activity of
TGF-β1 [31]. Constitutive TIEG expressionwas detected in both PDLs
and SCC-25 cells, and PDLs showed a significant (p<0.05, using
Mann–Whitney test), 2.8±0.6-times upregulation in co-culture
(Fig. 4D). The gene expression of TIMPs-1–3 and MMP-2 was
compared with that of TGFBR2 and TIEG in co-cultured vs. control
PDLs, where both TGFBR2 and TIEG showed highly significant
correlation with TIMPs-1–3 and MMP-2 (correlation coefficients
over 0.66, p<10−3, Supplementary Document 2).
Regulation of MMP and TIMP expression in co-cultured
tumor cells
MMP-1 and MMP-9 were constitutively expressed in SCC-25 cells,
and their gene expression was upregulated in co-cultured SCC-25
cells (Figs. 2A and F). Previously [12], we have shown that the IL-1
receptor is much lower expressed in SCC-25 cells than in PDLTable 2 – Tumor cell contribution to the MMP and TIMP expressio
Gene: n Change in SCC-2
co-culture vs. cont
MMP-1 20 13.8±3.7-times up
MMP-2 20 1.73±0.36-times up
MMP-3 20 Low expression
MMP-7 20 11.61±3.9-times up
MMP-9 20 1.35±0.5-times up
MT1-MMP 20 No change
TIMP-1 20 2.56±0.3-times up
TIMP-2 20 No change
TIMP-3 20 2.8±0.3-times upfibroblasts. Nevertheless, we have investigated if MMP-1 andMMP-9
are regulated by IL-1β in SCC-25 cells. Using the same time and
concentration ranges for the IL-1β-treatment as for PDLs, there were
no significant changes compared to control in SCC-25 cells (p=0.7
for MMP-1, p=0.24 for MMP-9 using non-parametric tests).
It was previously reported that fibronectin, via theαvβ6 integrin
receptor (ITGA5B6) might upregulate MMP-9 gene expression [32].
Since IL-1β-treatment did not significantly contribute to MMP-9
gene expression in SCC-25 cells, it was investigated, if fibronectin,
via ITGA5B6 receptor might have a contribution to MMP-9
regulation. Integrin αv (ITGA5) was constitutively expressed in
both PDLs and SCC-25 cells (Fig. 5A). In co-culture, it was
significantly upregulated in both of them (2.9±1-times in fibro-
blasts and 2±0.3-times in SCC-25 cells, using Mann–Whitney test)
(Fig. 5A), which has been confirmed at the protein level as well
(Fig. 5D). Integrin β6 (ITGB6) was expressed only in SCC-25 cells,
and its gene expression remained unchanged in co-culture (p=0.1,
using Mann–Whitney test, Fig. 5B). In SCC-25 cells both αv and β6
integrins were present, their expression levels were comparable
with the one of MMP-9 (Figs. 2F, 5A–B), and the SCC-25-specific
expression of ITGB6 was also comparable with the SCC-25-specific
expression of MMP-9.
Fibronectin, the ligand, was constitutively highly expressed in
PDLs (Figs. 5C, E), and 29.9±0.3-times lower in SCC-25 cells, in
co-culture its gene expression did not change significantly
(Fig. 5C, using parametric and non parametric tests). At the
protein level using an antibody specific for the EDA-domain of
fibronectin it was detected only in the PDL fibroblasts (Fig. 5E).
MMP-2 and -9 gelatinase activity in the co-culture of SCC-25
cells and ﬁbroblasts
MMP-2 and -9 were functionally analysed in gelatinase zymo-
graphy. Both supernatants and cell lysates of controls and co-
cultures (of both the SCC-25- and PDL-side) were used in this
assay. Active and inactive bands of MMP-9 and MMP-2 were
recognized, and active bands of these enzymes were found at
lower molecular weight. 5 μl of fetal bovine serum was used as
positive control (Figs. 6A–B, FBS lane).
In the cell lysates of PDL controls and co-culture only the
inactive pro-MMP-2 was recognized, which showed comparable
bands (Fig. 6A, lanes 1–2 and 5–6). In the cell lysates of SCC-25
control (Fig. 6A, lanes 3–4), three bands were recognized, the
inactive pro-MMP-9, the functional active MMP-9 and the inactive,n in co-culture of SCC-25 cells and CAFs.
5
rol
Test p
Mann–Whitney p<10−4
Unpaired t-test p=0.0528
Mann–Whitney p=0.052
Mann–Whitney p=0.002
Mann–Whitney p=0.36
Mann–Whitney p<10−4
Mann–Whitney p=0.13
Student's t-test p<10−4
Fig. 4 –mRNA expression of TGF-β1 (A), TGFBR2 (B), LTBP-1 (C) and TIEG (D) in fibroblasts and SCC-25 cells in control and co-cultured
conditions. *: p<0.05; **: p<0.01, ***: p<0.001.
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intensity increased (1.57±0.04 and 2.72±0.3-times respectively;
Fig. 6A, lanes 7–8, Figs. 6C, D), while pro-MMP-2-inactive showed
comparable bands in the cell lysate of control and co-cultured SCC-25
(Fig. 6A lanes 3–4 and 7–8). In the supernatants of PDL controls only
the inactive pro-MMP-2 was recognized (Fig. 6B, lanes 1–2). In co-
cultured PDLs inactive pro-MMP-9 appeared and the inactive pro-
MMP-2 bands decreased (Fig. 6B, lanes 5–6, Fig. 6E). In the
supernatants of SCC-25 control three bands were recognized, pro-
MMP-9 inactive, pro-MMP-2 inactive and MMP-2 active (Fig. 6B,
lanes 3–4). In co-culture the inactive pro-MMP-9 band intensity
increased (1.34±0.01-times; Fig. 6B, lanes 7–8), both pro-MMP-2-
inactive and MMP-2 active bands intensity increased significantly
(p<10−3 using Mann–Whitney test) (1.38±0.02-times and 1.27±
0.02-times Fig. 6B, lanes 7–8, Figs. 6E, F).
Taken together, MMP-9 showed tumor cell specific function, its
active form was only detected in/on the SCC-25 cells. MMP-2
showed fibroblast and tumor cell production (Fig. 6A), its active
formwas secreted, not found in cell lysates, and was present only at
the side of tumor cells. A co-culture led to increased representation
of active MMP-9 and MMP-2 either directly at the tumor cells, or in
their vicinity.Discussion
MMPs play a complex role in tumor progression andmetastasis. They
facilitate invasion by degrading components of the ECM and there is
also evidence that they are involved in angiogenesis. Tokumaru et al.
earlier showed that MMP-2 is activated by MT1-MMP, which is
localized on the cancer cells (Fig. 1A) [34].MT1-MMP is constitutively
expressed in SCC-25 cells, not regulated in co-culture with PDLs, and
is not expressed in PDLs in control and co-cultured conditions. MMP-
2 [35,36] and -9 are involved in the invasion process of oral cancer,
and MMP-9 is related to poor prognosis in the subset of patients
without neck node metastasis [37]. However, MMPs are not only
produced by tumor cells but also by stromal cells and tumor
infiltrating leucocytes, especially along the invasive front of the
tumor [37–39]. Tumors with strong MMP-2 expression in stromal
fibroblasts showed a significantly higher intratumoral microvessel
density (IMVD). In addition, postoperative prognosis of strong
stromal MMP-2 patients was significantly poorer than that of weak
stromal MMP-2 patients [40].
The results of this study suggest that MMP-2 is secreted in its
pro- (inactive-) form mainly by CAFs surrounding the tumor cells,
Fig. 5 –mRNA expression of ITGA5 (A), ITGB6 (B) and fibronectin (C), in PDL fibroblasts and SCC-25 cells in control and co-cultured
conditions. *: p<0.05; **: p<0.01, ***: p<0.001. Western blot of ITGA5 and loading control β-actin (D) in nuclear-free extracts of
control (1) and co-cultured (2) fibroblasts, control (3) and co-cultured (4) SCC-25 cells. Confocal microscopy of EDA-fibronectin
(red detected by Alexa fluor 647–conjugated anti-mouse IgG) in PDLs, bar: 100 μm.
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1A). Activation of MMP-2 either requires MT1-MMP localized on
the cancer cells (Table 2) [34], or integrins, where the involve-
ment of αv integrins (ITGA5, Figs. 5A, 1A) was reported in more
papers [41,42]. Our results show that the main contribution to the
activation of MMP-2 resides in the tumor cells, and might be due
to the constitutive expressed tumor-specific MT1-MMP. Never-
theless, CAFs play an essential role not only in the production of
pro-MMP-2, but also in influencing the activation of MMP-2 by
tumor cells. On the one hand ITGA5 is upregulated in CAFs, on the
other hand, the interplay between CAFs and tumor cells contrib-
utes to the upregulation of ITGA5 also in the tumor cells (Fig. 5A).
Interestingly, pro-MMP-2 is highly expressed in fibroblasts, but its
activation only occurred in the presence of tumor cells (Figs. 6A–
B). For the upregulation of MMP-2 also the interaction betweenfibroblasts and carcinoma cells was required, where the involve-
ment of the TGF-β1-pathway was recognized (Supplementary
Document 2) [43]. The paracrine interaction between oral SCC
cells and CAFs leads to the upregulation of other MMPs as of MMP-
1 and MMP-3. The clear involvement of tumor-produced IL-1β in
this process has been evidenced by the results of this work
(Fig. 1B), where the induction effect was reproduced in IL-1β-
treatments of fibroblasts. Several lines of evidence indicate that
fibroblasts might facilitate the invasion of SCC cells by expressing
MMPs on their own in response to tumor-cell-produced cytokines
(i.e. IL-1β), to TGF-β1 or to integrin–fibronectin interactions [41].
The tumor cells are capable of activating pro-MMPs.
In contrast to pro-MMP-2, pro-MMP-9 is produced by oral
carcinoma cells, not by fibroblasts. Pro-MMP-9 is activated on the
surface of tumor cells (Fig. 1A). The paracrine interaction between
Fig. 6 – Detection of MMP-2 and MMP-9 gelatinase activity in cell lysate (A) and supernatant (B) of fibroblasts and SCC-25 cells by
combined gelatinase zymography. 1–2: fibroblast control, 3–4: SCC-25 control, 5–6: fibroblast co-culture, 7–8: SCC-25 co-culture.
Densitometry of MMP-2 and MMP-9 gelatinase zymography (C–F). C and D represent the densitometry of pro-MMP-9 (C) and active
MMP-9 (D) bands in cell lysates. E and F show the densitometry of pro-MMP-2 (E) and active MMP-2 (F) form from supernatants.
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in oral carcinoma cells, where fibronectin, and its receptor, αvβ6
integrin [32] as well as CD-44 [44] could have been involved
(Fig. 1A).
Interestingly, besides their MMPs expression, fibroblasts pro-
duce several-fold higher amounts of inhibitors of metalloprotei-
nases (i.e. TIMPs) whose gene expression (especially of TIMP-1 and
TIMP-3) is also similarly upregulated in response to the paracrinecircuits between CAFs and oral carcinoma cells (Fig. 1B). In this
regulation, the inhibitory effect of dexamethasone suggests involve-
ment of inflammatory cytokines (Fig. 1B) (dexamethasone was also
able to inhibit the upregulation of MMPs-1–2 in co-cultured
fibroblasts, not shown), although, treatment of PDLs with IL-1β did
not change significantly the gene expression of TIMP-1 and TIMP-3.
In this regard, IL-1β might induce MMPs, but TIMPs are not
upregulated at the same time, which might lead to excess of matrix
1526 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 8 ( 2 0 1 2 ) 1 5 1 7 – 1 5 2 7degrading enzymes over their inhibitors. In fact, all TIMPs inhibit
active forms of all MMPs [45], in addition, they might contribute to
activation of pro-MMPs, as TIMP-1 to the activation of MMP-9 [46]
and TIMP-2 to the activation of MMP-2 [47].
Inflammatory cytokines could be, as mentioned before, selective
in activation ofMMPs and TIMPs, in addition, the TGF-β1-pathway is
also involved in the regulation of TIMP expression in CAFs
(Supplementary Document 2). A tissue of progressive tumor cells
and CAFs is characterized by high expression of TIMPs in fibroblasts,
and also by a significant TIMP expression in tumor cells. In fact, in co-
cultured SCC-25 cells MMP-1, MMP-2 and MMP-9 were higher
expressed than TIMP-1 or TIMP-2. These results allow the
assumption that; matrix in tumor tissue is probably not digested
by CAFs. In contrast, MMPs are also produced by tumor cells;
moreover, pro-MMP-9 was tumor-cell-specific, not found in
fibroblasts or CAFs. At the same time, tumor cells possess the tools
for activation of pro-MMPs, either as MT-MMPs, or TIMPs (as TIMP-
2 forMMP-2 [47]). TheMMP activationmight occur at the surface of
tumor cells or nearby individual tumor cells. The relation of MMP/
TIMP expression at this area allows activation ofMMPs at the surface
of tumor cells, which has been also seen experimentally using
gelatinase assays, finding active MMPs at the side of tumor cells in
co-culture. The tumor cell expression of TIMP-3 is relatively high,
but this TIMP is sequestered bound to extracellular matrix [45], and
will probably not be located close to the surface of tumor cells. In co-
culture, the diffusion of released MMPs is freely allowed by the
0.4 μm cell-culture inserts, but the tumor-cell-surface-associated
activation provides a continuous excess concentration of active
MMPs by the direct surface of tumor cells.
A coordination of the MMP–TIMP expression and MMP
activation between progressing OSCC tumor cells and CAFs leads
to local invasion potential of tumor cells, without a serious impact
on whole organ tissue remodeling.Conclusion
Several lines of evidence indicate that fibroblasts might facilitate
the invasion of OSCC cells, in part by paracrine regulatory circuits,
or by increasing the proteolytic activity of latent metalloprotei-
nases on the surfaces of OSCC cells.
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